Director, Market Access, Netherlands

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Market Access Director, Netherlands is responsible for defining and executing the country market access strategy to ensure timely, sustainable patient access to innovative oncology therapies. This role shapes reimbursement and access strategy, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities.

This position will partner with regulatory, commercial and medical affairs teams to deliver launch activities by providing access insights, developing evidence-based HTA, Pricing Reimbursement dossiers and tools, engaging with market access and public affairs stakeholders as well as driving pricing strategy activities, and lead the activities to deliver access results supporting the overall success of the product launches aligned with patient needs. Lead Market Access Reimbursement: Develop and implement strategies to support access and pricing decisions for RevMed portfolio and launches within the Netherlands healthcare system. HTA Pricing Filings: Lead preparation and submission of value dossiers, benefit assessments and pricing negotiations with statutory health insurance decision makers.

Partner with regional and local Medical Affairs and Marketing team to translate clinical and economic evidence into compelling value communications tailored for Netherlands payers. Build and maintain strong relationships with key external stakeholders (payers, HTA authorities, policy influencers). Representation of Revolution Medicines at local trade associations for market access subjects.

Work with Midsized Markets and Regional Market Access teams to align local access strategy with broader European and corporate objectives, especially in terms of aligning the European regulatory strategy and execution with local value dossier submission and pricing negotiation strategy. Provide early market access input to regional and European clinical development and medical teams. Lead negotiation with all levels of national payers.

Develop innovative pricing and value based contracting models to optimize the acceleration of reimbursement approvals. Policy Monitoring: Monitor health policy developments, HTA processes and local reimbursement environments to inform strategy. Represent Market Access in Netherlands Leadership Team meetings and contribute to overall business strategy.

Drive access and value related projects such as landscape assessments, payer market research, payer advisory boards and general guidance on local strategies. Development of outreach and engagement plan for key payers creating and maintaining a strong network. Early access planning of new products and indications, drive launch readiness for multiple oncology assets (portfolio responsibility).

Influence European and Midsised Markets access strategy based on local payer insights from a leadership position. Travel nationally and internationally. , Life Sciences, Pharmacy, Health Economics, Public Health).

A minimum of 10 years’ experience in market access, pricing, reimbursement or health economics (pharma/biotech) in Netherlands.